PDF(Pubmed)
Abstract：
UNASSIGNED: To analyze data available in the literature regarding a possible prognostic value of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in prostate cancer (PCa) patients stratified in non-metastatic and metastatic diseases.
UNASSIGNED: A literature search process was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. In our meta-analysis, the pooled event rate estimated and the pooled hazard ratio were calculated using a random effect model.
UNASSIGNED: Forty-two articles were selected for our analysis. The pooled risk difference for non-organ confined PCa between high and low NLR cases was 0.06 (95% confidence interval [CI]: -0.03-0.15) and between high and low PLR cases increased to 0.30 (95% CI: 0.16-0.43). In non-metastatic PCa cases, the pooled hazard ratio for overall mortality between high and low NLR was 1.33 (95% CI: 0.78-1.88) and between high and low PLR was 1.47 (95% CI: 0.91-2.03), whereas in metastatic PCa cases, between high and low NLR was 1.79 (95% CI: 1.44-2.13) and between high and low PLR was 1.05 (95% CI: 0.87-1.24).
UNASSIGNED: The prognostic values of NLR and PLR in terms of PCa characteristics and responses after treatment show a high level of heterogeneity of results among studies. These two ratios can represent the inflammatory and immunity status of the patient related to several conditions. A higher predictive value is related to a high NLR in terms of risk for overall mortality in metastatic PCa cases under systemic treatments.
UNASSIGNED: A literature search process was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. In our meta-analysis, the pooled event rate estimated and the pooled hazard ratio were calculated using a random effect model.
UNASSIGNED: Forty-two articles were selected for our analysis. The pooled risk difference for non-organ confined PCa between high and low NLR cases was 0.06 (95% confidence interval [CI]: -0.03-0.15) and between high and low PLR cases increased to 0.30 (95% CI: 0.16-0.43). In non-metastatic PCa cases, the pooled hazard ratio for overall mortality between high and low NLR was 1.33 (95% CI: 0.78-1.88) and between high and low PLR was 1.47 (95% CI: 0.91-2.03), whereas in metastatic PCa cases, between high and low NLR was 1.79 (95% CI: 1.44-2.13) and between high and low PLR was 1.05 (95% CI: 0.87-1.24).
UNASSIGNED: The prognostic values of NLR and PLR in terms of PCa characteristics and responses after treatment show a high level of heterogeneity of results among studies. These two ratios can represent the inflammatory and immunity status of the patient related to several conditions. A higher predictive value is related to a high NLR in terms of risk for overall mortality in metastatic PCa cases under systemic treatments.
摘要：
分析文献中关于在非转移性和转移性疾病中分层的前列腺癌(PCa)患者中血小板与淋巴细胞比率(PLR)和中性粒细胞与淋巴细胞比率(NLR)的可能预后价值的数据。
■按照系统评价和荟萃分析指南的首选报告项目进行文献检索。在我们的荟萃分析中，使用随机效应模型计算估计的合并事件率和合并风险比.
■我们选择了42篇文章进行分析。高和低NLR病例之间的非器官局限性PCa的合并风险差异为0.06（95％置信区间[CI]：-0.03-0.15），高和低PLR病例之间的合并风险差异为0.30（95％CI：0.16-0.43）。在非转移性PCa病例中，高和低NLR之间总死亡率的合并风险比为1.33（95％CI：0.78-1.88），高和低PLR之间为1.47（95％CI：0.91-2.03），而在转移性PCa病例中，高和低NLR之间为1.79(95%CI:1.44-2.13),高和低PLR之间为1.05(95%CI:0.87-1.24).
■就治疗后的PCa特征和反应而言，NLR和PLR的预后价值显示出研究中结果的高度异质性。这两个比率可以代表与几种病症相关的患者的炎症和免疫状态。就全身性治疗下转移性PCa病例的总死亡率风险而言，较高的预测值与高NLR相关。
■按照系统评价和荟萃分析指南的首选报告项目进行文献检索。在我们的荟萃分析中，使用随机效应模型计算估计的合并事件率和合并风险比.
■我们选择了42篇文章进行分析。高和低NLR病例之间的非器官局限性PCa的合并风险差异为0.06（95％置信区间[CI]：-0.03-0.15），高和低PLR病例之间的合并风险差异为0.30（95％CI：0.16-0.43）。在非转移性PCa病例中，高和低NLR之间总死亡率的合并风险比为1.33（95％CI：0.78-1.88），高和低PLR之间为1.47（95％CI：0.91-2.03），而在转移性PCa病例中，高和低NLR之间为1.79(95%CI:1.44-2.13),高和低PLR之间为1.05(95%CI:0.87-1.24).
■就治疗后的PCa特征和反应而言，NLR和PLR的预后价值显示出研究中结果的高度异质性。这两个比率可以代表与几种病症相关的患者的炎症和免疫状态。就全身性治疗下转移性PCa病例的总死亡率风险而言，较高的预测值与高NLR相关。
